Volume 70, Issue 3, Pages 552-554 (March 2019) Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring  Minou van Seyen, Elise J. Smolders, Peter van Wijngaarden, Joost P.H. Drenth, Marjan Wouthuyzen-Bakker, Robert J. de Knegt, Pieter Honkoop, Omar El-Sherif, Angela Colbers, David J. Back, David M. Burger  Journal of Hepatology  Volume 70, Issue 3, Pages 552-554 (March 2019) DOI: 10.1016/j.jhep.2018.10.010 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Pharmacokinetic curves of daclatasvir, sofosbuvir and GS-331007 in patients on contraindicated anti-epileptic drugs. (A) Daclatasvir standard dose of 60mg once daily was adjusted to 60mg twice daily for patient 1 and 2 and 60mg 3 times a day for patients 3–6, to compensate for the expected reduced exposure. For patient 2, the dose was further increased to 60mg 3 times a day (curve 2b) due to low exposure on 60mg twice daily (curve 2a). The reference curve shows daclatasvir 60mg once daily in hepatitis C genotype 1-infected patients without cirrhosis and contraindicated medication.10 Journal of Hepatology 2019 70, 552-554DOI: (10.1016/j.jhep.2018.10.010) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions